• Guardant Health’s third-quarter 2026 net loss widened 34% year over year to $124.36 million.
• Revenue rose 36% to $361 million, while Screening revenue more than doubled to $67.6 million year over year.
• Shield commercial coverage expanded to more than 80% of eligible lives; its lower-cost, higher-throughput workflow was fully deployed.
• Full-year 2026 revenue guidance increased to $1.36 billion–$1.37 billion, representing expected growth of 38%–40%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611051605BIZWIRE_USPR_____20261105_BW783458) on November 05, 2026, and is solely responsible for the information contained therein.